Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium study Academic Article uri icon

Overview

MeSH Major

  • Anticonvulsants
  • Antineoplastic Agents
  • Brain Neoplasms
  • Enzyme Induction
  • Glioblastoma
  • Glioma
  • Quinolones

abstract

  • Tipifarnib (300 mg bid for 21 days every 4 weeks) shows modest evidence of activity in patients with recurrent GBM who are not receiving EIAEDs and is generally well tolerated in this population.

publication date

  • August 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2006.06.2323

PubMed ID

  • 16877733

Additional Document Info

start page

  • 3651

end page

  • 6

volume

  • 24

number

  • 22